Shots:

• The approval is based on Detective Part 1 & Part 2 (TAF112582) and Gather (TAF116564) studies results assessing Krintafel (tafenoquine- 300mg) in 800 patients with relapse P.vivax malaria
• The study demonstrated with safety & effective results in global clinical development P.vivax relapse program built in collaboration with Medicines for Malaria Venture(MMV)
• Krintafel (tafenoquine- 300mg) is a novel single dose 8-aminoquinoline used as anti-relapse of P.vivax malaria- active against all stages of P.vivax lifecycle with its awaited TGA- Australia. Additionally- GSK received priority review voucher from FDA for Krintafel’s approval

Ref: GSK | Image: GSK